PR Newswire: news distribution, targeting and monitoring
2014
See more news releases in Health Care & Hospitals  | Medical Equipment  | Earnings

Masimo Reports First Quarter 2013 Financial Results

Q1 2013 Highlights (compared to Q1 2012):

- Total revenue, including royalties, rose 14% to $135.9 million

- Product revenue rose 15% to $128.6 million

- Masimo rainbow revenue rose 24% to $10.5 million

- Masimo SET® and Masimo rainbow® SET unit shipments rose 19% to 39,500

- Net income rose to $16.4 million, with EPS of $0.28 versus $0.27 in the year-ago period

Share with Twitter Share with LinkedIn

IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 30, 2013.

Masimo's total first quarter revenue, including royalties, rose 14% to $135.9 million, compared to $119.2 million for the first quarter of 2012.  First quarter 2013 product revenue rose 15% to $128.6 million, compared to $112.2 million for the first quarter of 2012.  The company's worldwide direct product revenue grew 13% in the first quarter of 2013 and represented 84% of product revenue.  OEM sales, which accounted for 16% of product revenue, rose 26% compared to the same period in 2012.  Revenue from sales of Masimo rainbow products rose 24% to $10.5 million in the first quarter, compared to $8.5 million for the first quarter of 2012.  

Net income for the first quarter of 2013 was $16.4 million, or $0.28 per diluted share, compared to net income of $15.8 million, or $0.27 per diluted share, in the first quarter of 2012.  First quarter 2013 earnings per share were reduced by approximately $0.03 due to non-operating expenses primarily related to realized and unrealized net losses on foreign currency denominated transactions due to the strengthening of the U.S. dollar against the Japanese yen.

During the first quarter, the company shipped approximately 39,500 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 19% compared to approximately 33,300 in the same prior-year period.  Masimo estimates its worldwide installed base as of March 30, 2013 to be 1,117,000 units, up 11% from 1,005,000 units as of March 31, 2012.      

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Masimo is off to a solid start in 2013, with product revenue up 15%, fueled by a 14% rise in our core SET Pulse Oximetry business and a 24% rise in sales of rainbow SET Pulse CO-Oximetry and other rainbow related products. The 19% increase in driver shipments in the quarter further underscores the growing demand for our superior technology in hospitals and alternate care settings worldwide.  In addition, we took advantage of strong cash flows in the quarter to repurchase 778,000 shares of Masimo common stock, demonstrating our confidence in the company's strategy, business model and future growth prospects."         

As of March 30, 2013, Masimo's cash and cash equivalents were $81.6 million, compared to $71.6 million as of December 29, 2012.  The change reflects primarily net cash generated from operations, offset by $12.4 million in cash used to repurchase approximately 778,000 shares of Masimo common stock. 

Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results.  A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at www.masimo.com.  The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers.  The reservation code for both dial-in numbers is 32475273.  After the live webcast, the call will be available on Masimo's website through June 2, 2013.  In addition, a telephonic replay of the call will be available through May 16, 2013.  The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 32475273.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. And in 2012, Masimo acquired the assets of Spire Semiconductor, LLC, a maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; and demand for our technologies.  These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements.  These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the integration of acquisitions; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at www.sec.gov.  Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise.  We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor Contact: Sheree Aronson


Media Contact: Mike Drummond

(949) 297-7043


(949) 297-7434

saronson@masimo.com


mdrummond@masimo.com   

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.

 


MASIMO CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited) (in thousands)










March 30,
2013


December 29,
2012

ASSETS




Current assets




Cash and cash equivalents

$      81,575


$      71,554

Accounts receivable, net of allowance for doubtful accounts

67,835


67,911

Royalties receivable

7,200


7,130

Inventories

48,462


47,358

Prepaid expenses

7,479


8,587

Deferred tax assets

12,879


12,911

Other current assets

3,105


3,896





Total current assets

228,535


219,347

Deferred cost of goods sold

54,823


52,103

Property and equipment, net

23,910


23,924

Intangible assets, net

27,767


27,363

Goodwill

22,789


22,824

Deferred tax assets

22,344


22,363

Other assets

7,659


8,022





Total assets

$   387,827


$    375,946





LIABILITIES AND EQUITY




Current liabilities




Accounts payable

$      30,876


$      27,033

Accrued compensation

21,460


25,021

Accrued liabilities

19,882


16,648

Income taxes payable

3,431


1,504

Deferred revenue

20,501


19,278

Current portion of capital lease obligations

114


55





Total current liabilities

96,264


89,539

Deferred revenue

454


576

Capital lease obligations, less current portion

239


60

Other liabilities

10,303


10,103





Total liabilities

107,260


100,278





Equity




Masimo Corporation stockholders' equity:




Common stock

57


57

Treasury stock

(79,045)


(63,664)

Additional paid-in capital

262,507


258,783

Accumulated other comprehensive income

3,695


3,542

Retained earnings

90,789


74,361





Total Masimo Corporation stockholders' equity

278,003


273,079

Noncontrolling interest

2,564


2,589





Total equity

280,567


275,668





Total liabilities and equity

$   387,827


$    375,946





 

 

MASIMO CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited) (in thousands, except per share amounts)






Three Months Ended


March 30,
2013


March 31,
2012

Revenue:




Product

$   128,635


$ 112,219

Royalty

7,307


7,009





Total revenue

135,942


119,228

Cost of goods sold

46,361


39,923





Gross profit

89,581


79,305

Operating expenses:




Selling, general and administrative

52,273


46,472

Research and development

14,167


10,505





Total operating expenses

66,440


56,977





Operating income

23,141


22,328

Non-operating expense

(2,326)


(582)





Income before provision for income taxes

20,815


21,746

Provision for income taxes

4,413


5,980





Net income including noncontrolling interest

16,402


15,766

Net loss attributable to the noncontrolling interest

26


8





Net income attributable to Masimo Corporation stockholders

$     16,428


$   15,774









Net income per share attributable to Masimo Corporation stockholders:




Basic

$          0.29


$        0.27





Diluted

$          0.28


$        0.27





Weighted average shares used in per share calculations:




Basic

57,240


58,178





Diluted

58,011


59,142





 

 

MASIMO CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited) (in thousands)






Three Months Ended


March 30,
2013


March 31,
2012

Cash flows from operating activities:




Net income including noncontrolling interest

$      16,402


$      15,766

Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:




Depreciation and amortization

2,783


1,760

Share-based compensation

3,413


3,804

Loss on disposal of property and equipment

78


Provision (benefit) for doubtful accounts

142


(217)

Provision for obsolete inventory

165


471

Provision for warranty costs

777


619

Income tax benefit from exercise of stock options granted prior to January 1, 2006

12


56

Excess tax deficit from share-based compensation arrangements

164


167

Changes in operating assets and liabilities:




Increase in accounts receivable

(72)


(3,496)

Increase in royalties receivable

(70)


(183)

Increase in inventories

(1,274)


(1,930)

(Increase) decrease in deferred cost of goods sold

(2,741)


1,119

Decrease in prepaid expenses

1,067


3,031

(Increase) decrease in other assets

1,128


(2,090)

Increase in accounts payable

3,874


1,268

Decrease in accrued compensation

(3,405)


(2,198)

Increase (decrease) in accrued liabilities

(436)


170

Increase in income taxes payable

1,779


4,141

Increase in deferred revenue

1,102


683

Increase in other liabilities

213


307





Net cash provided by operating activities

25,101


23,248





Cash flows from investing activities:




Purchases of property and equipment

(1,839)


(1,913)

Increase in intangible assets

(1,107)


(525)

Cash paid for acquisitions


(7,176)





Net cash used in investing activities

(2,946)


(9,614)





Cash flows from financing activities:




Repayments of capital lease obligations

(84)


(12)

Proceeds from issuance of common stock

463


275

Excess tax deficit from share-based compensation arrangements

(164)


(167)

Repurchases of common stock

(12,431)


(14,366)





Net cash used in financing activities

(12,216)


(14,270)





Effect of foreign currency exchange rates on cash

82


(398)





Net increase (decrease) in cash and cash equivalents

10,021


(1,034)

Cash and cash equivalents at beginning of period

71,554


129,882





Cash and cash equivalents at end of period

$      81,575


$    128,848





 

SOURCE Masimo Corporation



RELATED LINKS
http://www.masimo.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 
Area to test

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release